[
    [
        {
            "time": "2023-11-01",
            "original_text": "张磊再出手：高瓴资本斥资10亿入股A股上市公司凯莱英",
            "features": {
                "keywords": [
                    "高瓴资本",
                    "凯莱英",
                    "医药股",
                    "定增"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "张磊再出手：高瓴资本斥资10亿入股A股上市公司凯莱英",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 9,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        },
        {
            "time": "2023-11-01",
            "original_text": "焦点分析 | 10亿元拿下凯莱英，高瓴重金押注的CXO有何魅力？",
            "features": {
                "keywords": [
                    "高瓴",
                    "凯莱英",
                    "CXO",
                    "医药行业"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "焦点分析 | 10亿元拿下凯莱英，高瓴重金押注的CXO有何魅力？",
                "Correlation": 10,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 7,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "2023-11-01",
            "original_text": "高瓴资本再出手入股凯莱英，10亿狂买600亿医药股",
            "features": {
                "keywords": [
                    "高瓴资本",
                    "凯莱英",
                    "医药股",
                    "投资"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "高瓴资本再出手入股凯莱英，10亿狂买600亿医药股",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 9,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        },
        {
            "time": "2023-11-01",
            "original_text": "凯莱英拟将不超16亿元暂时闲置募集资金进行现金管理",
            "features": {
                "keywords": [
                    "凯莱英",
                    "募集资金",
                    "现金管理"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "凯莱英拟将不超16亿元暂时闲置募集资金进行现金管理",
                "Correlation": 9,
                "Sentiment": 6,
                "Importance": 6,
                "Impact": 5,
                "Duration": 4,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 7
            }
        },
        {
            "time": "2023-11-01",
            "original_text": "高瓴、高毅、景林三季度以来持仓曝光 医药、安防“榜上有名”",
            "features": {
                "keywords": [
                    "高瓴",
                    "高毅",
                    "景林",
                    "医药",
                    "安防"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "安防"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "高瓴、高毅、景林三季度以来持仓曝光 医药、安防“榜上有名”",
                "Correlation": 7,
                "Sentiment": 6,
                "Importance": 6,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 6,
                "Market_Scope": 8,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "2023-11-01",
            "original_text": "凯莱英定增一波三折终成行 发行价翻倍高瓴坚定布局A股医药版图",
            "features": {
                "keywords": [
                    "凯莱英",
                    "定增",
                    "高瓴",
                    "医药"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "凯莱英定增一波三折终成行 发行价翻倍高瓴坚定布局A股医药版图",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 9,
                "Duration": 8,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "2023-11-01",
            "original_text": "美的、宁德时代、凯莱英等标的创历史新高，北向资金回马枪扫货A股剑指这些板块！",
            "features": {
                "keywords": [
                    "凯莱英",
                    "北向资金",
                    "医药",
                    "历史新高"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "美的、宁德时代、凯莱英等标的创历史新高，北向资金回马枪扫货A股剑指这些板块！",
                "Correlation": 8,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 7,
                "Duration": 5,
                "Entity_Density": 7,
                "Market_Scope": 9,
                "Time_Proximity": 8,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        }
    ]
]